Your browser is no longer supported. Please, upgrade your browser.
Settings
BIOC Biocept, Inc. daily Stock Chart
BIOC [NASD]
Biocept, Inc.
Index- P/E- EPS (ttm)-3.96 Insider Own0.02% Shs Outstand13.40M Perf Week0.22%
Market Cap58.06M Forward P/E- EPS next Y-1.32 Insider Trans-34.54% Shs Float12.49M Perf Month1.35%
Income-25.40M PEG- EPS next Q-0.32 Inst Own14.90% Short Float3.18% Perf Quarter-32.88%
Sales10.70M P/S5.43 EPS this Y86.40% Inst Trans-12.49% Short Ratio0.66 Perf Half Y3.22%
Book/sh1.89 P/B2.38 EPS next Y37.40% ROA-89.80% Target Price- Perf Year-14.49%
Cash/sh1.31 P/C3.44 EPS next 5Y40.00% ROE-125.10% 52W Range2.11 - 13.00 Perf YTD56.99%
Dividend- P/FCF- EPS past 5Y- ROI-178.70% 52W High-65.46% Beta0.89
Dividend %- Quick Ratio2.50 Sales past 5Y110.60% Gross Margin-32.30% 52W Low112.59% ATR0.34
Employees88 Current Ratio2.90 Sales Q/Q340.00% Oper. Margin- RSI (14)47.93 Volatility4.96% 7.19%
OptionableYes Debt/Eq0.11 EPS Q/Q82.60% Profit Margin- Rel Volume0.63 Prev Close4.47
ShortableYes LT Debt/Eq0.06 EarningsNov 12 AMC Payout- Avg Volume598.38K Price4.49
Recom2.00 SMA20-2.43% SMA50-2.48% SMA200-13.01% Volume388,256 Change0.45%
Nov-14-17Reiterated Chardan Capital Markets Buy $2.50 → $1.50
Jun-02-17Initiated Chardan Capital Markets Buy $2.50
Jun-06-16Initiated ROTH Capital Buy $1.20
Aug-19-15Initiated H.C. Wainwright Buy $4
Jun-03-14Initiated Aegis Capital Buy $16
Nov-20-20 08:00AM  
Nov-17-20 08:05AM  
Nov-16-20 06:47PM  
Nov-14-20 07:52AM  
Nov-12-20 04:05PM  
02:30PM  
08:05AM  
Nov-09-20 08:05AM  
Nov-05-20 08:05AM  
Nov-04-20 08:00AM  
Oct-29-20 08:05AM  
Oct-21-20 08:00AM  
Oct-06-20 08:00AM  
Oct-05-20 08:00AM  
Oct-01-20 08:00AM  
Sep-24-20 08:48AM  
Sep-23-20 08:00AM  
Sep-21-20 06:21PM  
08:00AM  
Sep-16-20 08:00AM  
Sep-14-20 08:00AM  
Sep-09-20 08:00AM  
Sep-08-20 08:00AM  
Sep-04-20 04:28PM  
Aug-31-20 06:12PM  
09:24AM  
Aug-27-20 08:00AM  
Aug-24-20 08:00AM  
Aug-20-20 08:30AM  
Aug-19-20 08:00AM  
05:00AM  
Aug-18-20 08:00AM  
Aug-17-20 07:38PM  
Aug-13-20 08:00AM  
Aug-12-20 04:05PM  
Aug-06-20 11:44AM  
11:34AM  
08:00AM  
Aug-05-20 06:00PM  
11:15AM  
Aug-03-20 08:00AM  
Jul-31-20 02:43PM  
Jul-16-20 08:05AM  
Jun-30-20 08:05AM  
Jun-26-20 10:04PM  
Jun-24-20 08:05AM  
Jun-22-20 08:05AM  
Jun-05-20 08:05AM  
May-29-20 08:30AM  
May-20-20 08:05AM  
May-14-20 08:05AM  
May-13-20 04:05PM  
Apr-29-20 08:05AM  
Apr-28-20 08:05AM  
Apr-20-20 08:05AM  
Apr-14-20 09:00AM  
Apr-13-20 09:54AM  
Apr-09-20 07:17PM  
08:05AM  
Apr-02-20 08:05AM  
Apr-01-20 07:53PM  
Mar-28-20 08:23AM  
Mar-26-20 08:05AM  
Mar-25-20 04:05PM  
02:30PM  
Mar-18-20 08:30AM  
08:05AM  
Mar-11-20 09:23AM  
Mar-09-20 08:05AM  
Mar-05-20 08:30AM  
Mar-02-20 10:48AM  
08:30AM  
Feb-14-20 08:05AM  
Feb-10-20 08:05AM  
Feb-04-20 08:05AM  
Jan-14-20 08:05AM  
Jan-12-20 08:22AM  
Jan-08-20 09:00AM  
Dec-12-19 08:00AM  
Dec-10-19 07:56AM  
Dec-09-19 09:15AM  
Dec-03-19 08:05AM  
Nov-21-19 08:05AM  
Nov-13-19 04:05PM  
Nov-07-19 08:05AM  
Nov-06-19 08:05AM  
Nov-04-19 08:05AM  
Oct-14-19 10:05AM  
Oct-07-19 08:05AM  
Oct-03-19 08:05AM  
Sep-03-19 08:05AM  
Aug-22-19 08:05AM  
Aug-13-19 08:05AM  
Aug-12-19 04:05PM  
02:30PM  
Aug-05-19 08:05AM  
Aug-04-19 10:02PM  
Jul-22-19 08:05AM  
Jul-16-19 01:31PM  
Jun-18-19 08:05AM  
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HALE DAVID FDirectorJun 12Sale0.56604335112Jun 12 09:42 PM
HALE DAVID FDirectorJun 12Sale0.56556309867Jun 12 09:42 PM
ONCT Oncternal Therapeutics, Inc. daily Stock Chart
ONCT [NASD]
Oncternal Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.14 Insider Own5.00% Shs Outstand20.13M Perf Week-12.11%
Market Cap58.34M Forward P/E- EPS next Y-0.75 Insider Trans102.11% Shs Float14.15M Perf Month61.78%
Income-18.80M PEG- EPS next Q-0.21 Inst Own18.90% Short Float0.07% Perf Quarter3.67%
Sales2.50M P/S23.34 EPS this Y68.60% Inst Trans53.06% Short Ratio0.00 Perf Half Y-16.99%
Book/sh0.78 P/B3.26 EPS next Y27.90% ROA-91.90% Target Price- Perf Year-58.09%
Cash/sh- P/C- EPS next 5Y0.00% ROE-150.60% 52W Range1.49 - 6.28 Perf YTD-35.70%
Dividend- P/FCF- EPS past 5Y7.20% ROI-231.50% 52W High-59.55% Beta1.40
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low70.47% ATR0.49
Employees11 Current Ratio3.00 Sales Q/Q20.00% Oper. Margin- RSI (14)44.07 Volatility7.69% 21.10%
OptionableNo Debt/Eq0.02 EPS Q/Q31.50% Profit Margin- Rel Volume0.28 Prev Close2.57
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume2.48M Price2.54
Recom2.00 SMA20-20.81% SMA507.17% SMA200-7.60% Volume694,748 Change-1.17%
Nov-17-20 11:00PM  
05:28PM  
Nov-11-20 08:00AM  
Nov-10-20 10:51AM  
Nov-09-20 04:01PM  
Nov-04-20 05:15PM  
Oct-06-20 08:00AM  
Sep-22-20 07:00AM  
Sep-21-20 08:00AM  
Sep-10-20 08:00AM  
Sep-03-20 08:29AM  
Aug-27-20 09:18PM  
05:18PM  
Aug-06-20 04:15PM  
02:37PM  
Jul-30-20 08:00AM  
Jul-27-20 08:00AM  
Jul-20-20 08:00AM  
Jun-30-20 08:00AM  
07:45AM  
May-20-20 08:00AM  
May-19-20 08:00AM  
May-07-20 08:00AM  
May-05-20 08:00AM  
May-01-20 08:00AM  
Mar-18-20 08:36AM  
Mar-16-20 04:05PM  
Mar-11-20 04:08PM  
08:00AM  
Feb-06-20 08:00AM  
Dec-12-19 06:00PM  
Dec-11-19 08:00AM  
Dec-09-19 08:00AM  
Dec-03-19 08:00AM  
Nov-21-19 08:00AM  
Nov-14-19 04:02PM  
Nov-11-19 08:00AM  
Nov-07-19 04:05PM  
Nov-05-19 08:00AM  
Oct-31-19 08:00AM  
Oct-03-19 08:00AM  
Sep-20-19 12:03PM  
Sep-17-19 04:05PM  
Sep-09-19 08:00AM  
Aug-28-19 04:01PM  
Aug-08-19 04:01PM  
Aug-06-19 08:00AM  
Aug-01-19 04:01PM  
Jun-10-19 08:00AM  
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. It also develops TK-216, a small-molecule that is designed to inhibit E26 transformation specific family of oncoproteins, which is in Phase I clinical trial to treat patients with Ewing sarcoma and in combination with vincristine chemotherapy. In addition, the company develops a chimeric antigen receptor-T product candidate that targets ROR1, which is in preclinical development for treating hematologic cancers and solid tumors. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARTER MICHAEL GDirectorSep 01Buy2.1071,429150,00171,947Sep 02 04:53 PM
AKER HAZEL MLegal CounselJul 21Buy2.3841,97299,99846,987Jul 23 05:00 PM
KISNER DANIEL LDirectorJul 21Buy2.3810,00023,82510,000Jul 23 05:00 PM
Shanghai Pharmaceutical (USA) 10% OwnerJul 21Buy2.381,049,3172,499,9983,544,431Jul 23 04:32 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.